PBLS Parabilis Medicines, Inc.
Price Chart
Executive Summary
Parabilis Medicines insiders executed a massive $394.8M open-market purchase and converted millions of derivative shares for no cash on June 11, the same day the company closed its IPO and a $75M Regeneron PIPE. The $394.6M buy by RA Capital Management (a 10% owner/director) represents ~12.3% of the $3.2B market cap, an extraordinarily high conviction signal. Directors also received routine equity grants, and a second director bought $250K worth of shares. The strong alignment between the Regeneron strategic investment, the IPO closing, and insider buying indicates insiders are putting significant capital at risk at the $20/share price.
Key Financial Metrics
Actionable Insight
The $394.6M open-market buy by RA Capital at the IPO price of $20 is among the largest insider purchase clusters ever seen as a percentage of market cap. This signals that the company's largest pre-IPO holder is doubling down at the public listing price, providing a strong floor for the stock. Traders should watch for any lockup expiration (typically 180 days post-IPO) and monitor the Regeneron partnership for clinical catalysts. Short-term momentum from this signal should be expected.
Key Facts
- RA Capital Management bought 19.73M shares at $20/share for $394.6M in an open-market purchase, representing ~12.3% of market cap.
- Multiple directors converted derivative securities into common shares for $0 (non-cash) on June 11, the same day as the IPO closing.
- Director Alan Sebulsky bought 12,500 shares at $20 for $250K in an open-market purchase.
- The insider cluster coincided with the company's IPO and a $75M Regeneron private placement announced June 11.
- Six directors received equity grants (20K shares each, non-cash) on June 9, three days before the insider buying cluster.
Financial Impact
Insider purchases totaling $394.8M (12.3% of market cap) at $20/share, signaling extreme conviction from the largest shareholder and a director.
Risk Factors
- Lockup agreements will prevent any insider selling for at least 180 days, creating a potential overhang when they expire.
- The company is a pre-revenue biotech (implied by recent IPO) with no approved products or revenue stream mentioned in the filing.
- Dilution risk from the 4.17M shares issued to Regeneron at a 10% discount to IPO price.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PBLS-1781564346657 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 16, 2026
4d ago
|
Insider Cluster
| $26.03 $25.85 | ▼ −0.69% | ▼ −1.47% | $25.85 (−0.69%) |
|
Jun 15, 2026
5d ago
|
Insider Cluster
| $26.59 $26.03 | ▼ −2.11% | ▼ −0.86% | $25.85 (−2.78%) |
|
Jun 11, 2026
9d ago
|
8-K
| $27.26 $25.01 | ▼ −8.25% | ▼ −10.02% | $25.85 (−5.17%) |
|
Jun 10, 2026
10d ago
|
424B4
| $30.31 $27.26 | ▼ −10.06% | ▼ −10.60% | $25.85 (−14.71%) |
|
Jun 10, 2026
11d ago
|
EFFECT
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
|
Jun 10, 2026
11d ago
|
3
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
|
Jun 10, 2026
11d ago
|
3
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
|
Jun 10, 2026
11d ago
|
3
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
|
Jun 10, 2026
11d ago
|
3
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
|
Jun 10, 2026
11d ago
|
3
| $31.60 $30.31 | ▼ −4.08% | ▼ −5.78% | $25.85 (−18.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access